Literature DB >> 24356493

Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome.

S Barratt1, A R Medford, A B Millar.   

Abstract

Acute respiratory distress syndrome (ARDS) is the most severe form of lung injury, characterised by alveolar oedema and vascular permeability, in part due to disruption of the alveolar capillary membrane integrity. Vascular endothelial growth factor (VEGF) was originally identified as a vascular permeability factor and has been implicated in the pathogenesis of acute lung injury/ARDS. This review describes our current knowledge of VEGF biology and summarises the literature investigating the potential role VEGF may play in normal lung maintenance and in the development of lung injury.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24356493     DOI: 10.1159/000356034

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  32 in total

1.  Sp1-mediated nonmuscle myosin light chain kinase expression and enhanced activity in vascular endothelial growth factor-induced vascular permeability.

Authors:  Yuka Shimizu; Sara M Camp; Xiaoguang Sun; Tong Zhou; Ting Wang; Joe G N Garcia
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

2.  Syndecan-2 selectively regulates VEGF-induced vascular permeability.

Authors:  F Corti; E Ristori; F Rivera-Molina; D Toomre; J Zhang; J Mihailovic; Z W Zhuang; M Simons
Journal:  Nat Cardiovasc Res       Date:  2022-05-16

3.  Acute lung injury induced by acute uremia and renal ischemic-reperfusion injury: The role of toll-like receptors 2 and 4, and oxidative stress.

Authors:  Seyedeh-Sara Hashemi; Sahar Janfeshan; Zeinab Karimi
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

4.  Effects of Vascular Endothelial Growth Factor in Recovery Phase of Acute Lung Injury in Mice.

Authors:  Junfeng Song; Hui Lu; Xuyang Zheng; Xianmei Huang
Journal:  Lung       Date:  2015-09-28       Impact factor: 2.584

5.  Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity.

Authors:  Seyed Mohammadreza Bolandi; Zohreh Abdolmaleki; Mohammad-Ali Assarehzadegan
Journal:  Inflammopharmacology       Date:  2021-03-19       Impact factor: 4.473

6.  Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking.

Authors:  Xuedong An; Yuqing Zhang; Shenghui Zhao; Liyun Duan; Yingying Duan; Fengmei Lian; Xiaolin Tong
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

7.  Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients.

Authors:  Esther J Nossent; Alex R Schuurman; Tom D Y Reijnders; Anno Saris; Ilse Jongerius; Siebe G Blok; Heder de Vries; JanWillem Duitman; Anton Vonk Noordegraaf; Lilian J Meijboom; René Lutter; Leo Heunks; Harm Jan Bogaard; Tom van der Poll
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

8.  Lung Transcriptomics during Protective Ventilatory Support in Sepsis-Induced Acute Lung Injury.

Authors:  Marialbert Acosta-Herrera; Fabian Lorenzo-Diaz; Maria Pino-Yanes; Almudena Corrales; Francisco Valladares; Tilman E Klassert; Basilio Valladares; Hortense Slevogt; Shwu-Fan Ma; Jesus Villar; Carlos Flores
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Platelet Vascular Endothelial Growth Factor is a Potential Mediator of Transfusion-Related Acute Lung Injury.

Authors:  James P Maloney; Daniel R Ambruso; Norbert F Voelkel; Christopher C Silliman
Journal:  J Pulm Respir Med       Date:  2014

10.  The Vascular Endothelial Growth Factors-Expressing Character of Mesenchymal Stem Cells Plays a Positive Role in Treatment of Acute Lung Injury In Vivo.

Authors:  Yi Yang; Shuling Hu; Xiuping Xu; Jinze Li; Airan Liu; Jibin Han; Songqiao Liu; Ling Liu; Haibo Qiu
Journal:  Mediators Inflamm       Date:  2016-05-24       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.